Amarantus Subsidiary MANF Therapeutics Announces Publication in Science Magazine of Positive Animal Data for MANF in Treatment of Retinal Damage and Issuance of Retinal Patent in Japan Covering MANF and CDNF
Amarantus Subsidiary MANF Therapeutics Receives Notice of Allowance from U.S. Patent & Trademark Office Covering MANF Treatment of Diabetes
Amarantus Subsidiary Elto Pharma Announces the Issuance of Patents in Singapore and New Zealand Covering Treatment of Parkinson’s LID
Amarantus Subsidiary Elto Pharma Receives Notice of Allowance for European Patent Application Covering Method of Treating Cognitive Impairment Associated with Alzheimer's Disease and Parkinson's disease with Eltoprazine
Amarantus Provides Comprehensive Corporate Update
Amarantus Enters Into Forbearance and Capital Restructuring Agreements With Holders of Secured Debt, Convertible Preferred Stock and Warrants
Amarantus Forms Subsidiaries "Elto Pharma" to Focus on CNS Disorders and "MANF Therapeutics" to Focus on Ophthalmology
Amarantus Provides Update on Restructuring Efforts and Letter of Intent with SeD Biomedical, Inc.